U.S. Capital Markets Stock News

UWM Holdings has agreed to acquire Two Harbors Investment Corp (NYSE:TWO), creating fresh questions for mortgage and mortgage servicing investors. Management at UWM has offered limited detail on how Two Harbors will be integrated, including capital allocation, portfolio positioning, and leadership roles. Investors are reacting to sparse guidance around timing, financial impact, and operational changes, especially given existing financial pressures at Two Harbors. Two Harbors focuses on...

Vita Coco Company (COCO) is back in focus after its latest quarter showed revenue ahead of expectations, while earnings per share came in slightly below consensus, alongside fresh guidance for fiscal 2026. See our latest analysis for Vita Coco Company. At a share price of $58.06, Vita Coco has seen positive momentum recently, with a 7 day share price return of 7.60% and a 90 day share price return of 8.71%, while its 1 year total shareholder return of 78.98% and 3 year total shareholder...

Earlier this week, Clear Secure reported fourth-quarter and full-year 2025 results showing higher sales year over year, issued first-quarter 2026 revenue guidance of US$242–US$245 million, and announced both a 20% increase in its regular quarterly dividend to US$0.15 per share and a special US$0.20 per-share dividend alongside an expanded share repurchase authorization. The company also highlighted strong free cash flow generation, renewed its multiyear partnership with American Express, and...

If you have been wondering whether Kyndryl Holdings is starting to look like value or a value trap, this article walks through the numbers so you can judge that for yourself. The stock last closed at US$12.33, with returns of 1.4% decline over 7 days, 48.0% decline over 30 days, 51.6% decline year to date and 67.6% decline over 1 year. This naturally raises questions about how the market is currently pricing the business. Recent news around Kyndryl has focused on its position as a standalone...

NextDecade is preparing to report its fourth-quarter results on March 2, 2026, as it works to bring the Rio Grande LNG facility online while managing ongoing losses. A recent 20-year offtake agreement with EQT for 1.5 million tonnes per annum stands out as a key milestone in de-risking future LNG sales from the project. We’ll now examine how progress at Rio Grande LNG, including the EQT offtake deal, is shaping NextDecade’s broader investment narrative. Capitalize on the AI infrastructure...

United Therapeutics unveiled its new Tresmi soft mist inhaler platform, designed to improve patient experience in pulmonary hypertension treatment. The company reported record annual revenue alongside the Tresmi launch, underscoring progress across its commercial portfolio. Management also highlighted advances in late stage clinical programs, pointing to several upcoming trial readouts as key catalysts. United Therapeutics, traded as NasdaqGS:UTHR, comes into this news with a share price of...

Mobileye Global (NasdaqGS:MBLY) is adding Elektrobit’s Linux platform to its Mobileye Drive system to support Level 4 autonomous driving. The company recently secured a major U.S. OEM win for its advanced driver assistance systems, expanding its ADAS pipeline. Mobileye signed a SuperVision agreement with Mahindra & Mahindra, positioning itself as a Tier 1 supplier and opening new geographic markets. Mobileye Global, known for its driver assistance and autonomous driving technology, is...

If you are wondering whether Aveanna Healthcare Holdings is still attractively priced after its recent run, you are not alone. This article focuses on what the current share price could imply about value. The stock last closed at US$7.36, with returns of 0.3% over 7 days, a 10.8% decline over 30 days, an 8.9% decline year to date, and a 72.8% gain over the past year, as well as a very large 3 year return of around 4x. Recent coverage has centred on Aveanna's role in home and pediatric...

In late February 2026, Jazz Pharmaceuticals reported fourth‑quarter 2025 revenue of US$1,197.93 million and net income of US$203.45 million, contributing to record full‑year revenue of US$4.27 billion but a net loss of US$356.15 million. The company paired these results with guidance for 2026 revenue of US$4.25–4.50 billion and highlighted practice‑changing oncology data for zanidatamab and Ziihera, reinforcing its rare‑disease and cancer focus despite full‑year losses. Next, we’ll examine...

Why VeriSign Is On Investors’ Radar Today VeriSign (VRSN) is back in focus after a recent pullback, with the share price showing a negative return over the past month and past 3 months while longer term returns remain positive. See our latest analysis for VeriSign. The recent pullback, reflected in a 30 day share price return of 10.08% and a 90 day share price return of 9.54%, contrasts with a 3 year total shareholder return of 15.01% and a 5 year total shareholder return of 19.10%. This...

If you are wondering whether uniQure’s current share price reflects its true worth, this breakdown is designed to help you weigh what you are paying against what you are getting. The stock closed at US$15.63, with returns of a 33.3% decline over 7 days, a 32.1% decline over 30 days, a 33.2% decline year to date, but an 18.9% gain over the past year, which may catch the eye of investors thinking about both risk and recovery potential. Recent news around uniQure has focused on its position in...

Chair transition at Core Scientific comes as business model shifts toward AI infrastructure Core Scientific (CORZ) is back in focus after Chairman Jordan Levy told the board he will not stand for re election in 2026, as the company continues shifting toward AI focused data center operations. See our latest analysis for Core Scientific. The chairman news lands after a mixed share price stretch, with a recent 1 month share price return showing a 12.93% decline and a year to date share price...

LeMaitre Vascular (NasdaqGM:LMAT) reported robust Q4 2025 and full-year 2025 financial results. The company announced a new US$100 million share repurchase program. Management approved a 25% dividend increase for shareholders. LeMaitre Vascular focuses on medical devices for vascular surgeons, so its performance tends to track demand for procedures that treat peripheral vascular disease and related conditions. The combination of strong quarterly and full-year 2025 figures with higher...

Coca-Cola Consolidated (COKE) is back in focus after its 2025 earnings report, which highlighted record annual revenue and operating income alongside a sharp post-announcement share price run on heavy trading volume. See our latest analysis for Coca-Cola Consolidated. The earnings release sits on top of a powerful run in the stock, with a 30 day share price return of 35.57% and a year to date share price return of 35.08%, while the 5 year total shareholder return is close to 7x. This suggests...

Nike (NYSE:NKE) is adjusting its supply chain after a new 15% global tariff linked to recent U.S. trade policy changes. The company is accelerating efforts to reduce China based manufacturing for U.S. bound footwear. Nike is facing ongoing headwinds in the China market, with distributor profit warnings and speculation about restructuring tied to softer demand. Separately, Nike has signed an agreement to power its Japan operations with renewable energy, extending its sustainability...

Earlier this week, Commvault announced an expanded integration with CrowdStrike’s Falcon Next-Gen SIEM and a new STACKIT sovereign cloud partnership to enhance cyber-resilient, immutable backup and recovery options for enterprises, particularly in the European Union. Together, these moves highlight Commvault’s push to embed its data protection intelligence directly into leading security platforms while meeting rising data sovereignty demands through EU-jurisdictional, customer-controlled...

Crown Castle Inc. previously declared a quarterly cash dividend of US$1.0625 per common share, payable on March 31, 2026, to shareholders of record on March 13, 2026, while reporting fourth-quarter 2025 FFO that exceeded analyst estimates despite a year-over-year revenue decline. Alongside approving a 2026 restructuring plan and executive incentive program, Crown Castle is moving to sell its fiber business, intending to focus on its tower portfolio, repay debt, and repurchase shares, which...

Astronics Corporation recently reported its fourth-quarter 2025 and full-year results, with Q4 sales rising to US$240.07 million and net income improving to US$29.62 million, while full-year sales reached US$862.13 million alongside a return to profitability. The company paired this with 2026 revenue guidance of US$950 million to US$990 million and a record year-end backlog, signaling how current execution is feeding into a larger pipeline of future work even as near-term quarterly guidance...

Cheniere Energy Partners (CQP) closed out FY 2025 with Q4 revenue of US$2.9 billion and basic EPS of US$3.38, while trailing twelve month revenue sat at US$10.8 billion and EPS at US$6.17, supported by 45% earnings growth over the past year and a net profit margin of 27.8%. Over recent quarters, the partnership has seen revenue move from US$2.5 billion in Q4 2024, with EPS of US$1.05, to US$2.9 billion in Q4 2025 with EPS of US$3.38. This positions the latest earnings release as a...

In recent days, Ford Motor announced a very large recall of roughly 4.3 million pickup trucks, SUVs, and vans in the US to fix a software issue that can affect trailer braking and exterior lighting, alongside a separate recall of over 412,000 Explorer SUVs for rear suspension toe link defects. These recalls arrive just after Ford reported a net loss for 2025 and outlined plans to cut warranty costs, improve quality, and execute a refreshed product and electrification roadmap, putting its...

Senior executives at Vertex Pharmaceuticals (NasdaqGS:VRTX), including the SVP & Chief Accounting Officer and the Executive Vice President & Chief Legal Officer, have recently reported material insider stock sales. The transactions were carried out under regulatory trading plans, signaling fresh internal activity at the company. These insider moves come as Vertex reports financial performance and advances an expanding clinical pipeline. Vertex focuses on therapies for serious diseases, and...

If you are wondering whether Leggett & Platt is attractively priced or a value trap, starting with a clear view of its recent share performance and valuation checks can help bring that picture into focus. The stock last closed at US$11.68, with returns of 6.3% year to date and 30.1% over the past year, set against longer term 3 year and 5 year returns of 62.0% and 69.7% declines. Recent news around Leggett & Platt has mainly centered on its position in bedding and furniture components, and...

Fifth Third Bancorp (NasdaqGS:FITB) has completed its acquisition of Comerica Incorporated. The bank has issued special executive performance share unit awards tied to integration and shareholder alignment. New regional leaders have been appointed in Texas to oversee the combined operations as integration moves forward. For you as an investor, this deal brings Fifth Third further into commercial and consumer banking across key markets, with Texas now a more prominent focus. The acquisition...

In February 2026, Corcept Therapeutics reported that full-year 2025 net income fell to US$99.65 million from US$141.21 million a year earlier, while guiding 2026 net revenue to a range of US$900 million to US$1,000 million. At the same time, the company faced mounting legal and regulatory pressure, with multiple securities class actions filed after the FDA issued a Complete Response Letter requiring more evidence for its relacorilant New Drug Application in Cushing’s syndrome. We’ll now...